About
Evommune, Inc. (NYSE:EVMN) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 6 2026
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Mar 5 2026
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
Feb 13 2026
Evommune Announces $125 Million Private Placement
Feb 10 2026
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Dec 11 2025
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update